White House eyes ibogaine research funding for PTSD

The White House is drafting an executive order to open the door to federal funding for research on ibogaine, a psychedelic used abroad to treat PTSD and brain injuries. It would not reclassify the drug (still Schedule I) but signals support for further U.S. studies on safety and effectiveness, with a focus on veterans. Evidence is limited—mostly small observational studies—with notable cardiac risks and several deaths reported; a Stanford study suggested potential PTSD relief when ibogaine is paired with magnesium, yet more rigorous trials are needed before any medical use.